Australia markets closed

SpringWorks Therapeutics, Inc. (SWTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
43.91-0.09 (-0.20%)
As of 11:14AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 3.26B
Enterprise value 2.79B
Trailing P/E 21.09
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)509.91
Price/book (mrq)5.20
Enterprise value/revenue 511.56
Enterprise value/EBITDA -8.16

Trading information

Stock price history

Beta (5Y monthly) 0.82
52-week change 389.25%
S&P500 52-week change 325.01%
52-week high 353.92
52-week low 318.00
50-day moving average 347.67
200-day moving average 334.15

Share statistics

Avg vol (3-month) 31.14M
Avg vol (10-day) 3781.47k
Shares outstanding 574.06M
Implied shares outstanding 674.06M
Float 868.05M
% held by insiders 12.24%
% held by institutions 1107.55%
Shares short (28 Mar 2024) 410.66M
Short ratio (28 Mar 2024) 410.09
Short % of float (28 Mar 2024) 417.43%
Short % of shares outstanding (28 Mar 2024) 414.39%
Shares short (prior month 29 Feb 2024) 411.13M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,807.66%

Management effectiveness

Return on assets (ttm)-31.62%
Return on equity (ttm)-54.90%

Income statement

Revenue (ttm)5.45M
Revenue per share (ttm)0.09
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -341.35M
Net income avi to common (ttm)-325.1M
Diluted EPS (ttm)-5.15
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)479.2M
Total cash per share (mrq)6.5
Total debt (mrq)7.06M
Total debt/equity (mrq)1.13%
Current ratio (mrq)6.41
Book value per share (mrq)8.53

Cash flow statement

Operating cash flow (ttm)-222.8M
Levered free cash flow (ttm)-113.19M